BioSenic Puts Fracture Cell Therapy Program on Hold After Mid-Stage Failure

Belgium-based biotech company BioSenic has announced that it is suspending the development of its investigational allogeneic cell therapy derived from mesenchymal stem cells, called ALLOB, which was being assessed as a treatment for tibial fractures. The decision to pause ALLOB’s development comes after disappointing results in a Phase IIb trial, which had been designed to evaluate the candidate..